Increased revenues push up Julphar EBITDA by 13.5pc

Gulf Pharmaceutical Industries (Julphar), has seen EBITDA from continuing operations reaching AED45.4 million ($12.36 million) in Q1 2023 boosted by a 8.5% increase in revenue to AED454.1 million.

Related Keywords

Jordan ,Saudi Arabia ,Woman ,Khaimah ,Ras Al Khaymah ,United Arab Emirates ,Basel Ziyadeh ,Humaid Al Qasimi ,Tradearabia News Service ,Gulf Pharmaceutical Industries Julphar ,Pharmaceutical Industries ,Saqer Bin Humaid Al Qasimi ,Chief Executive Officer ,Arabia News ,Tradearabia ,Rade Arabia ,Iddle East Trade News ,Cc Business News ,Ndustry News ,Trade News ,Usiness Directory ,Enders ,Roject News ,Remium Content ,